keyword
https://read.qxmd.com/read/38534007/high-hepatitis-c-cure-rates-among-patients-with-alcohol-use-at-a-safety-net-hepatitis-c-clinic
#1
JOURNAL ARTICLE
Erica Heiman, Meghan Alexander, Rebecca Zhang, Ziduo Zheng, Lesley S Miller
OBJECTIVES: We set out to examine several aspects of the relationship between alcohol use and hepatitis C virus (HCV) among a cohort of patients treated at an HCV clinic within a safety net hospital. We examined (1) the prevalence of alcohol use among patients treated for HCV, (2) the likelihood of being started on treatment among patients who reported drinking alcohol compared with those who did not, and (3) the associations between alcohol use and HCV cure. METHODS: We performed a retrospective chart abstraction study using data from the Grady Liver Clinic, a specialty HCV clinic colocated in Grady Memorial Hospital's primary care clinic and run by general internists...
March 27, 2024: Journal of Addiction Medicine
https://read.qxmd.com/read/38522854/comparison-of-glecaprevir-pibrentasvir-and-sofosbuvir-ledipasvir-in-patients-with-hepatitis-c-virus-genotype-1-and-2-in-south-korea
#2
JOURNAL ARTICLE
Hyun Deok Shin, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Hyuk Soo Eun, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Seok Hwan Kim, Myung Joon Song, Soon Yeong Ko, Suk Bae Kim
BACKGROUND/AIMS: This study compared the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) in real-life clinical practice. METHODS: The data from genotype 1 or 2 chronic hepatitis C patients treated with GLE/PIB or sofosbuvir + ribavirin or SOF/LDV in South Korea were collected retrospectively. The analysis included the treatment completion rate, sustained virologic response at 12 weeks (SVR12) test rate, treatment effectiveness, and adverse events...
March 25, 2024: Korean Journal of Gastroenterology, Taehan Sohwagi Hakhoe Chi
https://read.qxmd.com/read/38516248/mitochondrial-dysfunction-affects-hepatic-immune-and-metabolic-remodeling-in-patients-with-hepatitis-b-virus-related-acute-on-chronic-liver-failure
#3
JOURNAL ARTICLE
Yu Zhang, Xiao-Ling Tian, Jie-Qun Li, Dong-Sheng Wu, Qiang Li, Bin Chen
BACKGROUND: Immune dysregulation and metabolic derangement have been recognized as key factors that contribute to the progression of hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF). However, the mechanisms underlying immune and metabolic derangement in patients with advanced HBV-ACLF are unclear. AIM: To identify the bioenergetic alterations in the liver of patients with HBV-ACLF causing hepatic immune dysregulation and metabolic disorders...
February 28, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38483035/direct-acting-antivirals-in-women-of-reproductive-age-infected-with-hepatitis-c-virus
#4
JOURNAL ARTICLE
Krystyna Dobrowolska, Małgorzata Pawłowska, Dorota Zarębska-Michaluk, Piotr Rzymski, Ewa Janczewska, Magdalena Tudrujek-Zdunek, Hanna Berak, Włodzimierz Mazur, Jakub Klapaczyński, Beata Lorenc, Justyna Janocha-Litwin, Anna Parfieniuk-Kowerda, Dorota Dybowska, Anna Piekarska, Rafał Krygier, Beata Dobracka, Jerzy Jaroszewicz, Robert Flisiak
Eliminating hepatitis C virus (HCV) infection in the population of women of reproductive age is important not only for the health of women themselves but also for the health of newborns. This study aimed to evaluate the implementation of this goal by analysing the effectiveness of contemporary therapy in a large cohort from everyday clinical practice along with identifying factors reducing therapeutic success. The analysed population consisted of 7861 patients, including 3388 women aged 15-49, treated in 2015-2022 in 26 hepatology centres...
March 14, 2024: Journal of Viral Hepatitis
https://read.qxmd.com/read/38463302/adenosine-deaminase-as-a-potential-diagnostic-and-prognostic-biomarker-for-severe-fever-with-thrombocytopenia-syndrome
#5
JOURNAL ARTICLE
Hongling Ye, Xiawen Lin, Zheng Zhang, Zhiye Xu, Taihong Huang, Shijie Cai, Yinyin Fan, Sen Wang
BACKGROUND: Severe fever with thrombocytopenia syndrome (SFTS) is a serious infectious disease caused by the Dabie bandavirus, with a high mortality rate. Currently, there are no effective vaccines or specific treatments for SFTS. Early diagnosis and accurate severity assessment are crucial. METHODS: This study included 171 cases of SFTS, COVID-19, and hepatitis B virus (HBV) patients and healthy controls. We compared the serum adenosine deaminase (ADA) activity across these groups...
March 5, 2024: ACS Omega
https://read.qxmd.com/read/38447754/heavily-treatment-experienced-persons-living-with-hiv-currently-in-care-in-italy-characteristics-risk-factors-and-therapeutic-options-the-icona-foundation-cohort-study
#6
JOURNAL ARTICLE
Sergio Lo Caputo, Mariacristina Poliseno, Alessandro Tavelli, Roberta Gagliardini, Stefano Rusconi, Giuseppe Lapadula, Andrea Antinori, Daniela Francisci, Loredana Sarmati, Andrea Gori, Vincenzo Spagnuolo, Francesca Ceccherini-Silberstein, Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri
OBJECTIVES: Heavily Treatment-Experienced (HTE) People Living with HIV (PLWH) pose unique challenges due to limited antiretroviral treatment (ART) options. Our study aimed to investigate the prevalence and features of HTE individuals followed up inthe ICONA cohort as of December 31, 2021. METHODS: HTE were defined based on meeting specific conditions concerning their current ART and their ART history up to December 31, 2021.Descriptive statistics were performed by HTE status...
March 4, 2024: International Journal of Infectious Diseases: IJID
https://read.qxmd.com/read/38446182/-liver-transplantation-in-viral-and-autoimmune-liver-diseases
#7
REVIEW
Christian M Lange, Tobias J Weismüller, Christian P Strassburg
BACKGROUND: Despite substantial progress in the management of viral and autoimmune liver diseases, these entities remain relevant indications for liver transplantation. AIMS: To provide an overview of the current knowledge regarding the management of viral and autoimmune liver diseases before and after liver transplantation. MATERIALS AND METHODS: Selective literature search, including current guidelines and abstracts of key scientific meetings...
March 6, 2024: Inn Med (Heidelb)
https://read.qxmd.com/read/38427290/direct-acting-antivirals-remain-cost-effective-treatments-for-chronic-hepatitis-c-in-australia-despite-changes-to-the-treated-population-and-the-availability-of-retreatment-the-glecaprevir-pibrentasvir-maviret-%C3%A2-example
#8
JOURNAL ARTICLE
Emma Warren, Belinda J C Castles, Gillian C Sharratt, Aitor Arteaga
INTRODUCTION: The first direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection were reimbursed via Australia's Pharmaceutical Benefits Scheme (PBS) in March 2016. This was based on the recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) that the regimens would be acceptably cost-effective at an incremental cost-effectiveness ratio (ICER) no greater than $15,000/quality-adjusted life-year (QALY). Since the initial PBS listings for DAA therapies and subsequent listings of newer DAA treatments such as glecaprevir/pibrentasvir (Maviret® ), the demographics and some of the disease characteristics of currently treated patients have markedly changed...
March 1, 2024: Infectious Diseases and Therapy
https://read.qxmd.com/read/38357421/real-world-effectiveness-of-voxilaprevir-velpatasvir-sofosbuvir-in-patients-following-daa-failure
#9
JOURNAL ARTICLE
Christiana Graf, Roberta D'Ambrosio, Elisabetta Degasperi, Stefania Paolucci, Jordi Llaneras, Johannes Vermehren, Georg Dultz, Kai-Henrik Peiffer, Fabian Finkelmeier, Eva Herrmann, Stefan Zeuzem, Maria Buti, Pietro Lampertico, Julia Dietz, Christoph Sarrazin
BACKGROUND & AIMS: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed in an integrative analysis of three large real-world cohorts. METHODS: Consecutive patients re-treated with VOX/VEL/SOF after DAA failure were enrolled between 2016 and 2021 in Austria, Belgium, Germany, Italy, Spain and Switzerland...
March 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38355095/clinical-profile-of-spanish-hepatitis-c-virus-infected-treatment-na%C3%A3-ve-patients-with-compensated-cirrhosis-in-the-crest-study
#10
JOURNAL ARTICLE
Francisco Jorquera, Francisco Ledesma, Adriana Ahumada, María Luisa Manzano, Agustín Castiella, Sara Lorente, Mireia Miquel, Zoe Mariño, José Castellote, Eva Sanz, Juan Uriz
BACKGROUND AND AIM OF THE STUDY: There are still patients with hepatitis C in Spain who have yet to be diagnosed, but their clinical profile is unclear. In 2021, 21.93% of patients diagnosed had cirrhosis and were mostly treatment-naïve. METHODS: This sub-analysis describes the clinical profile of the 60 Spanish treatment-naïve patients with compensated cirrhosis who were included in the CREST study. MAJOR RESULTS: Sixty percent of patients were male, median age 56 years, and 33% had a history of drug use...
February 12, 2024: Gastroenterología y Hepatología
https://read.qxmd.com/read/38352660/post-transplant-diabetes-mellitus-risk-factors-and-outcomes-in-a-5-year-follow-up
#11
JOURNAL ARTICLE
Matheus Rizzato Rossi, Marilda Mazzali, Marcos Vinicius de Sousa
INTRODUCTION: Kidney transplantation is associated with an increased risk of posttransplant diabetes mellitus (PTDM), impacting recipient and graft survivals. The incidence of PTDM ranges from 15% to 30%, with most cases occurring in the first year post-transplant. Some clinical and laboratory characteristics pre- and post-transplant may be associated with a higher PTDM incidence in a more extended follow-up period. This study aimed to analyze the prevalence of PTDM among renal transplant recipients without previous DM diagnosis during a five-year post-transplant follow-up, as well as clinical and laboratory characteristics associated with a higher incidence of PTDM during this period...
2024: Front Clin Diabetes Healthc
https://read.qxmd.com/read/38320798/-research-progress-of-direct-acting-antiviral-drugs-in-the-treatment-of-chronic-hepatitis-c-related-cirrhosis
#12
JOURNAL ARTICLE
Y F Zhao, L Xu, Y Q Mi
Chronic hepatitis C is a kind of viral hepatitis caused by hepatitis C virus infection, which can further progress to cirrhosis, liver failure, hepatocellular carcinoma, and even death. Presently, there is no preventive vaccine yet. Therefore, preventing infection and safe and effective drug treatment are currently the most effective strategies for dealing with hepatitis C virus infection. Since 2014, the clinical application of direct-acting antiviral drugs has brought revolutionary changes to the treatment of chronic hepatitis C...
January 20, 2024: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://read.qxmd.com/read/38290716/targeting-virus-specific-cd8-t-cells-for-treatment-of-chronic-viral-hepatitis-from-bench-to-bedside
#13
REVIEW
Julia Lang-Meli, Christoph Neumann-Haefelin, Robert Thimme
INTRODUCTION: More than 350 million people worldwide live with chronic viral hepatitis and are thus at risk for severe complications like liver cirrhosis and hepatocellular carcinoma (HCC). To meet the goals of the World Health Organization (WHO) global hepatitis strategy, there is an urgent need for new immunotherapeutic approaches. These are particularly required for chronic hepatitis B virus infection and - B/D coinfection. AREAS COVERED: This review summarizes data on mechanisms of CD8+ T cells failure in chronic hepatitis B, D, C and E virus infection...
January 30, 2024: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/38287425/exploration-of-a-hypoxia-immune-related-microenvironment-gene-signature-and-prediction-model-for-hepatitis-c-induced-early-stage-fibrosis
#14
JOURNAL ARTICLE
Chuwen Chen, Haozheng Cai, Junyi Shen, Xiaoyun Zhang, Wei Peng, Chuan Li, Haopeng Lv, Tianfu Wen
BACKGROUND: Liver fibrosis contributes to significant morbidity and mortality in Western nations, primarily attributed to chronic hepatitis C virus (HCV) infection. Hypoxia and immune status have been reported to be significantly correlated with the progression of liver fibrosis. The current research aimed to investigate the gene signature related to the hypoxia-immune-related microenvironment and identify potential targets for liver fibrosis. METHOD: Sequencing data obtained from GEO were employed to assess the hypoxia and immune status of the discovery set utilizing UMAP and ESTIMATE methods...
January 29, 2024: Journal of Translational Medicine
https://read.qxmd.com/read/38261859/sofosbuvir-velpatasvir-voxilaprevir-for-hepatitis-c-virus-retreatment-in-difficult-to-treat-patients-a-real-life-observational-study-from-india
#15
JOURNAL ARTICLE
Harshita Katiyar, Mrunal Kamat, Ameet K Mandot, Amit Goel, Surender Singh, Ajay K Mishra, Rajani Singh, Prachi Tiwari, Radha K Dhiman, Samir Shah
BACKGROUND AND AIM: Hepatitis C virus (HCV) treatment fails to achieve sustained virological response at 12 weeks (SVR12) in 5-10 % and requires retreatment with second-line drugs. We report our experience of sofosbuvir/velpatasvir/voxilaprevir use for HCV retreatment in a small cohort of difficult-to-treat Indian patients. METHODS: We reviewed our HCV databases to identify the patients who had failed to achieve SVR12 after treatment with sofosbuvir in combination with either daclatasvir, ledipasvir, or velpatasvir with/without ribavirin on one or more occasions...
2024: Journal of Clinical and Experimental Hepatology
https://read.qxmd.com/read/38251444/late-presentation-for-hepatitis-c-treatment-prevalence-and-risk-factors-in-the-swiss-hepatitis-c-cohort
#16
JOURNAL ARTICLE
Nathalie Brunner, Thomas Grischott, Philip Bruggmann
OBJECTIVE: Patients with 'late presentation' (LP) of chronic hepatitis C infection (HCV) have already developed advanced liver disease before receiving direct-acting antiviral (DAA) treatment. Even after successful treatment, the risk of morbidity and premature death remains elevated, leading to an unnecessary disease burden. This study aimed to assess the prevalence of LP within the prospective observational Swiss Hepatitis C Cohort (SCCS) and evaluate risk factors as determinants of LP...
January 22, 2024: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/38220241/efficacy-and-safety-of-glecaprevir-and-pibrentasvir-in-saudi-patients-with-chronic-hepatitis-c-virus-infection-at-a-major-tertiary-hospital
#17
JOURNAL ARTICLE
Ali A Ruwayni, Eman E AlObary, Khalid M Alyahya
OBJECTIVES: To evaluate the effectiveness and safety of glecaprevir/pibrentasvir (GLE/PIB) in chronic hepatitis C (HCV) patients, and to assess the prescribers' adherence to Food and Drug Administration recommendations on treatment duration. METHODS: A retrospective cohort study was carried out on chronic HCV patients of ≥18 years, with or without cirrhosis, naive or experienced, and with normal kidney function or chronic kidney disease (including dialysis patients) at Prince Sultan Military Medical City in Riyadh, Saudi Arabia, between February 2020 and March 2021...
January 2024: Saudi Medical Journal
https://read.qxmd.com/read/38203503/crispr-cas9-as-a-new-antiviral-strategy-for-treating-hepatitis-viral-infections
#18
REVIEW
Ulyana I Bartosh, Anton S Dome, Natalya V Zhukova, Polina E Karitskaya, Grigory A Stepanov
Hepatitis is an inflammatory liver disease primarily caused by hepatitis A (HAV), B (HBV), C (HCV), D (HDV), and E (HEV) viruses. The chronic forms of hepatitis resulting from HBV and HCV infections can progress to cirrhosis or hepatocellular carcinoma (HCC), while acute hepatitis can lead to acute liver failure, sometimes resulting in fatality. Viral hepatitis was responsible for over 1 million reported deaths annually. The treatment of hepatitis caused by viral infections currently involves the use of interferon-α (IFN-α), nucleoside inhibitors, and reverse transcriptase inhibitors (for HBV)...
December 26, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38203436/hepatitis-c-virus-and-the-host-a-mutual-endurance-leaving-indelible-scars-in-the-host-s-immunity
#19
REVIEW
Mario U Mondelli, Sabrina Ottolini, Barbara Oliviero, Stefania Mantovani, Antonella Cerino, Dalila Mele, Stefania Varchetta
Hepatitis C virus (HCV) has spread worldwide, and it is responsible for potentially severe chronic liver disease and primary liver cancer. Chronic infection remains for life if not spontaneously eliminated and viral persistence profoundly impairs the efficiency of the host's immunity. Attempts have been made to develop an effective vaccine, but efficacy trials have met with failure. The availability of highly efficacious direct-acting antivirals (DAA) has created hope for the progressive elimination of chronic HCV infections; however, this approach requires a monumental global effort...
December 23, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38198667/prevention-and-treatment-of-cardiovascular-disease-in-hiv-practical-insights-in-an-evolving-field
#20
JOURNAL ARTICLE
Harris Avgousti, Matthew J Feinstein
People with HIV (PWH) are at higher risk for cardiovascular disease (CVD) than people without HIV. As antiretroviral therapy (ART) and the natural history of HIV have evolved, so have the pathogenesis and manifestations of HIV-associated CVD. Epidemiologic data from several cohorts demonstrate that PWH have an approximately 50% higher risk than people without HIV for CVD, including, but not limited to, myocardial infarction and heart failure. This elevated CVD risk is not universal among PWH; for instance, the risk is higher among individuals with a history of sustained unsuppressed viremia, diminished CD4+ cell count recovery, or hepatitis C virus coinfection...
December 5, 2023: Topics in Antiviral Medicine
keyword
keyword
169803
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.